Search

Search
Generic filters
Roche’s subcutaneous formulation of Tecentriq demonstrates positive Phase III results

Roche’s subcutaneous formulation of Tecentriq demonstrates positive Phase III results

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq® (atezolizumab) met its co-primary endpoints. The study showed non-inferior levels of Tecentriq in the blood (pharmacokinetics), when injected subcutaneously, compared with intravenous (IV) infusion, in cancer immunotherapy-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) for whom prior platinum therapy has failed.
Vitamin K prevents cell death: a new function for a long-known molecule

Vitamin K prevents cell death: a new function for a long-known molecule

Vitamin K is well-known for its blood clotting and bone building properties but today a new study published in Nature reports on a novel function for vitamin K.

The researchers discovered that the fully reduced form of vitamin K acts as an antioxidant efficiently inhibiting ferroptotic cell death. Ferroptosis is a natural form of cell death in which cellular iron plays an important role and which is characterized by the oxidative destruction of cellular membranes.

Bayer Consumer Health leaders propose new principles for science-led self-care

Bayer Consumer Health leaders propose new principles for science-led self-care

Bayer has published a new paper, Science-Led Self-Care: Principles for Best Practice, that sets out five key Principles that should underpin all self-care products improving personal health and wellness. The paper is intended to spark a conversation within the industry and its key stakeholders around the need to promote science-led self-care for the benefit of consumers.
GSK signs agreement to support pandemic preparedness in Europe

GSK signs agreement to support pandemic preparedness in Europe

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission’s (EC) Health Emergency Preparedness and Response Authority (HERA) for the reservation of future production and supply of 85 million doses of its pandemic influenza vaccine Adjupanrix [pandemic influenza vaccine (split virion, inactivated, adjuvanted)].
Disparities in United States COVID-19 vaccine distribution

Disparities in United States COVID-19 vaccine distribution

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populations or their reduced access to health care facilities. But new research from University of California San Diego and collaborating institutions has identified an additional barrier to equity: whether or not each health care facility actually received and administered vaccines.
New needle-free nasal vaccine shows promise for COVID-19

New needle-free nasal vaccine shows promise for COVID-19

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mBio, an open access journal of the American Society for Microbiology.

In recent years, the Food and Drug Administration authorized mRNA- and adenovirus-based SARS-CoV-2 vaccines.

Scientists develop new biomimetic formulation for treating glioblastoma

Scientists develop new biomimetic formulation for treating glioblastoma

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore urgently needed.

Based on observation of elevated lactate in resected GBM, researchers from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences and Shenzhen Second People’s Hospital have developed a

SARS-CoV-2 hijacks nanotubes between neurons to infect them

SARS-CoV-2 hijacks nanotubes between neurons to infect them

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both during the acute phase of the disease and over the long term with “long COVID” syndrome. But the way in which the infection reaches the brain was previously unknown. Scientists from Institut Pasteur and CNRS laboratories have used state-of-the-art electron microscopy approaches to demonstrate that SARS-CoV-2 hijacks nanotubes, tiny bridges that link infected cells with neurons.
Demonstration of a potent, universal coronavirus monoclonal antibody therapy for all COVID-19 variants

Demonstration of a potent, universal coronavirus monoclonal antibody therapy for all COVID-19 variants

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses.

Researchers discovered a neutralizing monoclonal antibody that potentially acts as a potent universal coronavirus therapy against SARS-CoV-2 and all its variants of concern, including Beta, Gamma, Delta, Epsilon and Omicron.

Back to Top
Product has been added to your cart